[go: up one dir, main page]

AU2001232337A1 - Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance - Google Patents

Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance

Info

Publication number
AU2001232337A1
AU2001232337A1 AU2001232337A AU3233701A AU2001232337A1 AU 2001232337 A1 AU2001232337 A1 AU 2001232337A1 AU 2001232337 A AU2001232337 A AU 2001232337A AU 3233701 A AU3233701 A AU 3233701A AU 2001232337 A1 AU2001232337 A1 AU 2001232337A1
Authority
AU
Australia
Prior art keywords
reagent
pharmaceutical composition
active ingredient
pharmaceutically active
labeling substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232337A
Inventor
Noriaki Kondo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kanagawa Academy of Science and Technology
Mitsubishi Chemical Corp
Original Assignee
Kanagawa Academy of Science and Technology
Mitsubishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kanagawa Academy of Science and Technology, Mitsubishi Chemical Corp filed Critical Kanagawa Academy of Science and Technology
Publication of AU2001232337A1 publication Critical patent/AU2001232337A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001232337A 2000-02-18 2001-02-19 Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance Abandoned AU2001232337A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-41303 2000-02-18
JP2000041303 2000-02-18
PCT/JP2001/001167 WO2001060411A1 (en) 2000-02-18 2001-02-19 Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance

Publications (1)

Publication Number Publication Date
AU2001232337A1 true AU2001232337A1 (en) 2001-08-27

Family

ID=18564561

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232337A Abandoned AU2001232337A1 (en) 2000-02-18 2001-02-19 Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance

Country Status (3)

Country Link
US (1) US20030050227A1 (en)
AU (1) AU2001232337A1 (en)
WO (1) WO2001060411A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1411968B1 (en) * 2001-07-31 2008-09-17 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Glp-1 exendin-4 peptide analogs and uses thereof
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
IL161251A0 (en) 2001-10-10 2004-09-27 Neose Technologies Inc Remodeling and glycoconjugation of peptides
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
CA2519092C (en) 2003-03-14 2014-08-05 Neose Technologies, Inc. Branched water-soluble polymers and their conjugates
EP1613261A4 (en) 2003-04-09 2011-01-26 Novo Nordisk As INTRACELLULAR FORMATION OF PEPTIDE CONJUGATES
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
ATE540055T1 (en) 2003-05-09 2012-01-15 Biogenerix Ag COMPOSITIONS AND METHODS FOR PRODUCING HUMAN GROWTH HORMONE GLYCOSYLATION MUTANTS
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
US20050170019A1 (en) * 2003-10-22 2005-08-04 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells
WO2005039291A2 (en) * 2003-10-22 2005-05-06 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells
US20050136125A1 (en) * 2003-10-22 2005-06-23 Roth Mark B. Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP1694347B1 (en) 2003-11-24 2013-11-20 BioGeneriX AG Glycopegylated erythropoietin
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US8361961B2 (en) 2004-01-08 2013-01-29 Biogenerix Ag O-linked glycosylation of peptides
RU2006138181A (en) 2004-05-04 2008-06-10 Ново Нордиск Хелс Кеа Аг (Ch) O-RELATED Glycoforms of Polypeptides and a Method for Their Production
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
US8268967B2 (en) 2004-09-10 2012-09-18 Novo Nordisk A/S Glycopegylated interferon α
SI2586456T1 (en) 2004-10-29 2016-05-31 Ratiopharm Gmbh Remodeling and glycopegylation of fibroblast growth factor (FGF)
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
CA2605631A1 (en) * 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
EP1888098A2 (en) 2005-05-25 2008-02-20 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
US20080242607A1 (en) 2006-07-21 2008-10-02 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
KR20100016160A (en) 2007-04-03 2010-02-12 바이오제너릭스 에이지 Methods of treatment using glycopegylated g-csf
JP5876649B2 (en) 2007-06-12 2016-03-02 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ Improved process for producing nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN101965200B (en) 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 Conjugated factor VIII molecules

Also Published As

Publication number Publication date
WO2001060411A1 (en) 2001-08-23
US20030050227A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
AU2001232337A1 (en) Pharmaceutical composition, reagent and method for intracerebral delivery of pharmaceutically active ingredient or labeling substance
HUP0303891A3 (en) Pharmaceutically active piridine derivatives, process for their preparation and pharmaceutical compositions containing them
IL145983A0 (en) Pharmaceutical composition for dermal use, comprising a corticosteroid and a vitamin d or an analogue thereof
AU2879100A (en) Formulation and system for intra-oral delivery of pharmaceutical agents
HUP0301325A3 (en) Stabilized pharmaceutically effective composition and pharmaceutical composition comprising the same and process for preparation the composition
AU7601998A (en) Composition and methods for transdermal delivery of acid labile drugs
HUP0301688A3 (en) Amino alcohol derivatives, process for their preparation and pharmaceutical compositions containing them
HUP0101512A3 (en) Adhesive microsphere drug delivery composition, process for its preparation and device containing it
AU2001226029A1 (en) Pharmaceutical formulation and method for pulmonary and oral delivery
EE05506B1 (en) Drug delivery device, especially for administration of progestins and strogens
AU2002236647A1 (en) Method and device for administering medication and/or placebo
AU2003215245A1 (en) Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
AU2001234114A1 (en) Drugs containing combined active ingredients
AU1307399A (en) Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same
HUP0204202A3 (en) Ibuprofen containing active agent preparation, process for its preparation and pharmaceutical compositions containing it
WO2001041742A3 (en) Antiviral medication
HUP0202934A3 (en) Arylsulfonamido-substituted hydroxamic acid derivatives, process for their preparation, pharmaceutical compositions containing them and use thereof
WO1998008517A3 (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
IL123927A (en) Propanolamine derivatives processes for their preparation and pharmaceutical composition comprising them
HUP0102369A3 (en) Amino acid derivatives and drugs containing the same as the active ingredient
HUP0401369A3 (en) Pharmaceutical formulation comprising (r)-bicalutamide, process for its preparation and use thereof
AU5072000A (en) Pharmaceutical composition for nasally administering water-soluble active substances
HUP0203212A3 (en) Integrin inhibitors, process for preparation thereof, their use preparation of pharmaceutical compositions and the compositions
AU2001260089A1 (en) Pharmaceutical compositions comprising desglymidodrine as an active drug substance
AU2570001A (en) Pharmaceutical composition and method for its manufacture